Cargando…
Innovative therapeutic strategy using prostaglandin I(2) agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension
Clinical outcomes of pulmonary arterial hypertension (PAH) may be improved using targeted delivery system. We investigated the efficacy of ONO1301 (prostacyclin agonist) nanospheres (ONONS) in Sugen5416/hypoxia rat models of PAH. The rats were injected with saline (control) or ONONS (n = 10, each) o...
Autores principales: | Kanaya, Tomomitsu, Miyagawa, Shigeru, Kawamura, Takuji, Sakai, Yoshiki, Masada, Kenta, Nawa, Nobutoshi, Ishida, Hidekazu, Narita, Jun, Toda, Koichi, Kuratani, Toru, Sawa, Yoshiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012709/ https://www.ncbi.nlm.nih.gov/pubmed/33790393 http://dx.doi.org/10.1038/s41598-021-86781-3 |
Ejemplares similares
-
A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and/or regeneration in the damaged heart
por: Fukushima, Satsuki, et al.
Publicado: (2015) -
A novel prostaglandin I(2) agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice
por: Motegi, Satoko, et al.
Publicado: (2022) -
Synthetic Prostacyclin Agonist Attenuates Pressure-Overloaded Cardiac Fibrosis by Inhibiting FMT
por: Masada, Kenta, et al.
Publicado: (2020) -
Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis
por: Tada, Satoru, et al.
Publicado: (2019) -
Successful treatment of graft-duodenal fistula after renovisceral debranching thoracic endovascular aortic repair with limited graft resection based on (18)F-fluorodeoxyglucose positron emission tomography with computed tomography
por: Matsumoto, Ryota, et al.
Publicado: (2021)